Day: May 21, 2024

BW Energy: Invitation to Q1 2024 results presentation 24 May BW Energy will release its first quarter 2024 results on Friday 24 May at 07:30 CEST. A conference call followed by Q&A will be hosted by CEO Carl K. Arnet, CFO Knut R. Sæthre and COO Lin G. Espey the same day at 14:00 CEST. You can follow the presentation via webcast with supporting slides, available on: Viewer Registration • Q1 2024 (webcast.no)   Call-in information Participants dial in numbers: DK: +45 7876 8490 SE: +46 8 1241 0952 NO: +47 2195 6342 UK: +44 203 769 6819 US: +1 646-787-0157 Singapore: 65-3-1591097 France: 33-1-81221259 PIN code: 980877   For further information, please contact: ir@bwenergy.no About BW Energy: BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased...

SHANGHAI, China, May 21, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today congratulated Lynk & Co on the first deliveries of the Lynk & Co 07 EM-P sedan, which is integrated with ECARX’s full-stack solution for digital cockpit and ADAS including Antora® 1000 Pro, Skyland Pro, and Flyme Auto. The EM-P 07 began deliveries on May 17, 2024. The Lynk & Co 07 EM-P was officially unveiled at the Beijing Auto Show 2024 in April, where it attracted immediate and significant interest from consumers, with orders in excess of 10,000 vehicles. The 07 EM-P is the second Lynk & Co model to launch with ECARX’s full-stack solution, following the highly successful launch of the 08 EM-P in September 2023. Over the Chinese Labor Day holiday at the...

Meeting Will be Held at The Hilton Hotel, San Francisco, CA SAN FRANCISCO, May 21, 2024 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that its Annual Meeting of Shareholders will be held on Tuesday, June 25, 2024, at 9:00 a.m. PT. The Annual Meeting will be an in-person meeting. For those who wish to attend, the meeting will be held at The Hilton Hotel, 750 Kearny St., San Francisco, CA, 94108. The Board of Directors fixed the close of business on April 26, 2024, as the record date for determination of shareholders entitled to notice of and to vote at the Annual Meeting. About American Shared Hospital Services (NYSE American:...

WINNEMUCCA, Nev., May 21, 2024 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce its proposed Grassy Mountain gold mine will have the benefit of a joint reclamation bond between the Oregon Department of Geology and Mineral Industries (the “DOGAMI”) and the Bureau of Land Management (“BLM”). The two agencies have executed a Memorandum of Understanding (“MOU”) which ensures that Paramount will not be required to post two reclamation bonds, thereby reducing capital requirements, and lessening the administrative burden. The approach undertaken by the DOGAMI and BLM aligns with how environmental bonding has been established in the mining friendly jurisdiction of Nevada. Upon submission of the reclamation cost estimate by the Company, the DOGAMI and BLM will determine...

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis model Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with Phase 1 clinical data expected in Q1 2025 Poster presentation today at 12:30 pm ET  BOSTON, May 21, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at Digestive Disease Week (DDW) 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of...

MONTVALE, N.J., May 21, 2024 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the Deutsche Bank Global Consumer Conference on June 4, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, and Martin Bengtsson, Chief Financial Officer will attend the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition &...

LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND submission Strong balance sheet with cash of $94.6 million supports runway into 2026UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2024. “LAVA continues to advance our pipeline of Gammabody programs and is excited...

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its proprietary algorithm, ICP Premium™. ICP will receive a fee of CDN $7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an Initial Term of three (3) months and shall be automatically renewed for subsequent one (1) month terms (each month called an “Additional Term“) unless either party provides at least thirty (30) days written notice prior to the end of the...